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1. Introduction
   Thrombotic Thrombocytopenic Purpura (TTP) is a 
thrombotic microangiopathy, characterized by the 
formation of microthrombi within vessels of multiple 
organ systems, leading to microangiopathic hemolytic 
anemia, thrombocytopenia, and potentially end organ 
ischemia. TTP was first described by E. Moschowitz in 1925 
“as a new disease characterized by unique pathological 
findings of hyaline thrombi in many organs”[1]. A classic 
pentad of thrombocytopenia, microangiopathic hemolytic 
anemia (MAHA), fever, neurological symptoms and renal 
abnormalities was described by Amorosi and Ultmann 
in 1966 and was present in 88%-98% of patients at that 
time[2]. With the advent of plasmapheresis as a first-line 
treatment modality for TTP, and the lower threshold for 
initiation of treatment, the number of patients presenting 
with the classic pentad was down to 40% in a study from 
1981[3]. Nowadays however, with the number of patients 
diagnosed with TTP up 8-fold, and with the increasing use 
of plasmapheresis early in the course of the disease, the 
number of patients who presented with the classic pentad 
is down to 5%[4]. An essential dyad of thrombocytopenia 
and MAHA in the appropriate clinical setting is now the 
only requirement for establishing a diagnosis of TTP and 
initiating treatment[4]. We describe an atypical case of TTP 
that demonstrates an ambiguous presentation in a patient 
with clinical manifestations that were explained by other 
diseases. 
2. Casereport
  A previously healthy 44-year-old female presented to the 
Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy with an 
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found to have thrombocytopenia but only mild anemia that was explained by another disease 
process. Case: A 44-year-old female presented to the Emergency Department for worsening 
headache and weakness over the last week. She had no fever and no focal neurological deficits 
but was pale and complained of severe headache. A blood test showed her to be anemic and 
thrombocytopenic. She explained that she had been having prolonged heavy menses over the last 
year. She was treated with blood and platelet transfusions, and seen by the Gynecology service 
who treated her for uterine fibroids after which she was discharged. She returned 1 week later 
with the same complaint, and was found to have a stable hemoglobin level but recurrence of 
thrombocytopenia. A TTP diagnosis was entertained and the workup confirmed it. The patient 
was treated with plasmapheresis and discharged home with no sequalae. Conclusion: Emergency 
physicians should keep TTP in mind when approaching cases of thrombocytopenia with mild 
anemia, even if an alternative diagnosis exists.
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Emergency Department (ED) with generalized weakness and 
intermittent diffuse headache, associated with photophobia 
for the past week.
  Three days prior to the ED visit she was seen at an urgent 
care clinic for the same symptoms and discharged home 
with a diagnosis of viral syndrome. The following day she 
returned to the urgent care clinic with worsening of her 
symptoms and was treated with intravenous fluids and 
prescribed azithromycin for a presumed infection. Two days 
later she came to the ED with no improvement in symptoms 
and a chief complaint of generalized weakness and diffuse 
headache. During this ED visit, she reported having been 
diagnosed with uterine fibroids the previous year, and 
having prolonged and irregular heavy menses since then. 
The patient’s other previous medical history included 
anemia and autoimmune thyroiditis for which the patient 
underwent radioiodine ablation. The patient’s social history 
was negative for alcohol or drug use and she was a non-
smoker. Her family history was negative for systemic lupus 
erythematosus (SLE) or rheumatoid arthritis.
  On physical examination, the patient had stable vital signs. 
She had generalized pallor including skin, conjunctiva, 
palms, and nail beds. The neurological examination showed 
no focal deficit. A pelvic examination showed no blood in the 
vaginal vault, with a closed cervix and no adnexal masses 
or tenderness. Laboratory workup showed a hemoglobin 
(Hgb) level of 5 g/dL and a platelet count of 24 000/毺L, 
with normal prothrombin time (PT), partial thromboplastin 
time (PTT), fibrinogen and fibrinogen degradation products. 
The gynecological service was consulted and the patient 
was admitted to the observation unit with a diagnosis of 
menorrhagia, and treated with packed red blood cells and 
a platelet transfusion, with a post transfusion hemoglobin 
of 10 g/dL and platelet count greater than 50 000/毺L. She 
remained hemodynamically stable throughout her stay, 
and was discharged home after receiving a progesterone 
injection.
  One week later she presented again to the ED with severe 
headache, mostly frontal, associated with photophobia 
and continuous for the past 24 h. On the morning of her 
presentation, her menses had started and she was passing 
clots with intermittent heavy bleeding. She denied any prior 
upper respiratory tract infection, or easy bruising. Vital signs 
on presentation were: Temperature 36.3 ℃, Blood Pressure 
114/61 mmHg, Pulse 86 beats/min, Respiratory Rate 14/min, 
and O2 Saturation 100% on Room Air. On pelvic examination, 
the patient had mild active vaginal bleeding with a closed 
cervical os and palpable uterine masses consistent with her 
history of uterine fibroids. The neurological examination was 
normal with no deficit. Initial laboratory examination showed 
her hemoglobin was stable at 9.8 g/dL (previous value 10 g/
dL) but platelets had decreased to 17 000/毺L. Her creatinine 
level had increased to 1.1 mg/dL (previous creatinine: 0.8 
mg/dL) indicating possible early effect on her kidneys. 
  The ED physicians considered the previous anemia, 
and the persistent thrombocytopenia, and entertained the 
diagnosis of TTP. Laboratory examination for hemolysis was 
positive with elevations in lactate dehydrogenase (LDH) and 
reticulocyte count, up to 643 IU/L (100-220 IU/L) and 4.9% 
respectively. Unconjugated bilirubin was also elevated with 
total bilirubin at 1.7 mg/dL and direct bilirubin at 0.3 mg/dL. 
Haptoglobin levels were low at 16.2 mg/dL (30-200 mg/dL). 
Coombs test was negative while the peripheral smear was 
positive for schistocytes.
  Autoimmune profile was significant for strongly positive 
antinuclear antibodies (ANA), normal serum complement 
levels, positive ribonucleoprotein antibodies, and an 
ADAMTS-13 level of < 5% (Normal > 67%).
  The patient was admitted to the general medical floor 
and started on daily plasmapheresis. She showed gradual 
improvement in her platelet counts initially; however, she 
subsequently became thrombocytopenic again with a nadir 
of 39 K. Plasmapheresis was continued and the patient was 
started on prednisone. She improved and was weaned off 
plasmapheresis gradually and discharged home. 
3. Discussion
  Thrombotic Thrombocytopenic Purpura is an acute life-
threatening syndrome characterized by thrombocytopenia 
and microangiopathic hemolytic anemia. There is often 
multi-organ involvement with neurological and renal 
abnormalities being most common and potentially the most 
serious[5]. A classic pentad of thrombocytopenia, MAHA, 
fever, neurological abnormalities and renal dysfunction has 
been described but is rarely seen in its entirety nowadays[4]. 
Two major diagnostic criteria, thrombocytopenia and 
microangiopathic hemolytic anemia without alternate 
explanation form an essential dyad and are enough to 
suspect the diagnosis of the TTP and initiate treatment[4,5].
  Hemolytic Uremic Syndrome (HUS) shares these essential 
diagnostic criteria. Although sometimes grouped with TTP 
in the medical literature, there is debate over whether TTP 
and HUS are in fact distinct syndromes[6]. For the purposes 
of this article, they will be treated as such, because each has 
its own pathophysiology, optimal treatment and prognosis. 
Initial treatment, however, is the same for both and 
patients in the Emergency Department should be managed 
with plasma exchange until a definitive diagnosis can be 
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established[4]. 
  MAHA is defined as hemolysis with a negative direct 
antiglobulin (Coombs test), and red cell fragmentation 
(schistocytes) seen on peripheral smear. A few schistocytes 
seen on peripheral smear can be normal, especially in 
patients with renal disease, preeclampsia, or mechanical 
heart valves but the number is almost always less than 
0.5 percent[6]. Patients with TTP are expected to have >1% 
schistocytes on peripheral smear with one study finding the 
mean to be 8.4%[7]. Therefore, observation of two or more 
schistocytes in a microscopic field at 100× magnification 
suggests the presence of microangiopathic hemolysis[6]. 
  Indirect bilirubin and LDH are typically elevated as 
would be expected with hemolysis. Thrombocytopenia can 
be severe but can also be masked by schistocytes being 
incorrectly interpreted as platelets[6]. 
  About 50% of TTP cases are considered idiopathic[6]. 
Idiopathic TTP is related to decreased levels of a specific 
von Willebrand factor (VWF) cleaving protease, called 
ADAMTS-13 (A Disintegrin and Metalloprotease with a 
ThromboSpondin type 1 motif, member 13). Deficiency of 
ADAMTS-13 causes abnormally high platelet consumption 
and has been linked to patients with TTP and especially 
those who are at risk for relapse[6,8]. ADAMTS-13 acts to 
cleave VWF when it is partially unfolded by high levels of 
shear stress. By cleaving VWF before it is activated fully 
by shear stress, ADAMTS-13 prevents accumulation of 
super-active forms of VWF and subsequently prevents 
VWF–platelet aggregation[8,9]. When ADAMTS-13 is not 
present, abnormally large von Willebrand factor multimers 
accumulate in plasma and have a greater ability to react 
with platelets, causing disseminated platelet thrombi 
characteristic of thrombotic thrombocytopenic purpura[6]. 
This explains why a severe deficiency of ADAMTS-13, 
conventionally considered to be less than 5% activity 
(Normal is >67%), causes microvascular thrombosis that is 
characteristic of TTP[7,8].
  Researchers looking into causes of severe ADAMTS-
13 deficiency have found evidence of both congenital 
ADAMTS-13 deficiency (called Upshaw Schulman syndrome 
when it causes TTP)[9], and an autoimmune etiology, where 
autoantibodies to ADAMTS-13 were found in cases of TTP 
with severe ADAMTS-13 deficiency[4,10]. Furthermore, the 
association with other autoimmune disorders, namely SLE 
and certain vasculitides, and the frequent occurrence of 
a TTP like picture in patients with autoimmune disorders 
suggests that idiopathic TTP with severe ADAMTS13 
deficiency may represent an autoimmune disorder[9,10].
  Not all patients with idiopathic TTP have severe deficiency 
of ADAMTS-13. In a study by Hovinga et al. from 2010 that 
analyzed 107 patients with idiopathic TTP, only 51 patients 
had severe ADAMTS-13 deficiency[11]. Those patients with 
ADAMTS-13 deficiency did however have some distinctions. 
They were younger, had more severe anemia and 
thrombocytopenia, and less severe renal failure. Mortality 
was the same in both groups of patients but the risk of 
relapse was much higher (40%) among patients with severe 
ADAMTS-13 deficiency[11]. Therefore ADAMTS-13 activity 
level should not be used for diagnosis, and treatment should 
never be delayed waiting for results of this test.
  Although many cases of TTP are considered idiopathic, 
a number of underlying causes have been discovered. 
Hemolytic uremic syndrome consists of hemolytic anemia, 
thrombocytopenia, and renal impairment. HUS most 
often results from exposure to Shiga toxin produced by 
Escherichia coli or Shigella species resulting in a prodrome 
of bloody diarrhea. Essential diagnostic criteria for HUS, 
MAHA and thrombocytopenia, matches those of TTP and 
it is often treated as such, although in children, HUS is 
managed with only supportive care. Autoimmune TTP is a 
category of TTP associated with diseases such as systemic 
lupus erythematosus, antiphospholipid syndrome and 
collagen vascular diseases. People with these diseases 
have a higher incidence of TTP, and antibodies against 
ADAMTS-13 have been discovered in some[4-6]. Drug 
induced TTP is mostly commonly attributed to quinine, an 
over-the-counter medication used for leg cramps[4], but 
also found in tonic water. Other drugs that may induce TTP 
include the antiplatelet agents Ticlopidine and Clopidogrel, 
and immunosuppressants like Cyclosporine[5]. Certain 
chemotherapies may also cause TTP but the onset is usually 
insidious and is believed to be dose-dependent. The 
mechanism is also different and is most likely related to 
direct endothelial injury inciting the event[6]. It should also 
be noted that pregnancy may be a trigger of TTP in patients 
with congenital or acquired severe ADAMTS-13 deficiency 
as it is associated with a decrease of ADAMTS-13 by as 
much as 30%[5].
  First-line therapy for TTP is plasma exchange, which 
has an 80% success rate and is often curative[6], although 
relapses are common. Plasma exchange reverses the platelet 
consumption responsible for the thrombus formation and 
symptoms that are characteristic of this disorder[4]. It is 
believed that clinical improvement results from depletion 
of circulating levels of autoantibody to ADAMTS-13 if 
present, and likely also depletes the circulating very high 
molecular weight von Willebrand factor multimers[6]. If some 
improvement occurs after plasma infusion alone, it is likely 
as a result of replacement of the missing protease ADAMTS-
13[6].
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  Those patients diagnosed with TTP with severe 
ADAMTS-13 deficiency may benefit from the addition 
of glucocorticoids or rituximab[4,5]. Plasma transfusion is 
a second-line treatment modality and used mostly as a 
temporizing measure while preparing for plasma exchange. 
Without rapid intervention, TTP has a reported mortality rate 
as high as 90%, which drops to around 10-20% with plasma 
exchange[5,6].
  Acute morbidities include stroke/transient ischemic 
attacks, myocardial infarction, arrhythmias, bleeding, 
and renal failure. Survivors generally have no long-term 
sequalae, with the exception of residual neurologic deficits 
in a minority of patients. Relapses occur in around 13%-36% 
of patients with the likelihood of recurrence dependent on a 
number of recognized risk factors, which include ADAMTS-
13 deficiency and pregnancy after a previous episode of 
TTP[8]. A randomized trial of 102 patients by Rock, Shumak, 
Buskard et al. found the relapse rate to be 50% in patients 
with severe ADAMTS-13 deficiency[12].
  There is limited data available on patients with TTP who 
are not treated. The data available shows that without 
treatment, the disease is often rapidly progressive and 
fatal, with death most often occurring within 1-2 weeks 
from the onset of symptoms[2,8]. Our case demonstrates 
an insidious case of TTP. The patient’s only symptoms 
were weakness and headache, and during the 2 weeks 
before she received plasma exchange, she had almost no 
progression in her symptoms other than a worsening of 
her headache. The patient’s history of uterine fibroids and 
menorrhagia, with subsequent anemia was distracting and 
offered an alternative diagnosis that negated a laboratory 
examination for hemolysis during her first ED visit. To 
further distract physicians away from a diagnosis of TTP 
during her second ED visit, her hemoglobin was relatively 
stable after receiving the blood and platelet transfusion 
one week earlier (during her first ED visit.) In Ridolfi and 
Bell’s 1981 review of 237 cases of TTP, only 3% of cases (6 
of 237) had normal hematocrit values[3]. O’Brien and Crum 
hypothesized that: “Even the rare patient without anemia 
presumably exhibits fragmented red cells on a peripheral 
smear with a compensatory reticulocytosis”[13]. Our patient 
matches O’Brien and Crum’s prediction with only borderline 
anemia but with schistocytes on a peripheral smear and 
compensatory reticulocytosis.
  Emergency physicians in particular should keep TTP 
in mind when evaluating cases of combined anemia and 
thrombocytopenia, even when the anemia is mild or when 
an alternative diagnosis exists. A peripheral smear can 
help identify TTP or other thrombotic microangiopathies 
if there is hesitation to order a full laboratory examination 
for hemolysis. Physicians should also remember that the 
absence of fever, neurological deficits, renal abnormalities, 
or skin findings should not be used to rule out TTP.
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